Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dolby Laboratories (DLB) EBT (2016 - 2025)

Historic EBT for Dolby Laboratories (DLB) over the last 17 years, with Q4 2025 value amounting to $71.6 million.

  • Dolby Laboratories' EBT fell 1679.12% to $71.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $289.0 million, marking a year-over-year decrease of 902.15%. This contributed to the annual value of $303.5 million for FY2025, which is 287.83% down from last year.
  • Per Dolby Laboratories' latest filing, its EBT stood at $71.6 million for Q4 2025, which was down 1679.12% from $41.7 million recorded in Q3 2025.
  • Dolby Laboratories' 5-year EBT high stood at $121.7 million for Q1 2024, and its period low was $9.0 million during Q3 2023.
  • Moreover, its 5-year median value for EBT was $59.4 million (2021), whereas its average is $67.0 million.
  • Per our database at Business Quant, Dolby Laboratories' EBT plummeted by 7083.68% in 2023 and then skyrocketed by 56128.64% in 2024.
  • Quarter analysis of 5 years shows Dolby Laboratories' EBT stood at $91.4 million in 2021, then increased by 9.34% to $100.0 million in 2022, then fell by 19.15% to $80.8 million in 2023, then rose by 6.46% to $86.1 million in 2024, then decreased by 16.79% to $71.6 million in 2025.
  • Its last three reported values are $71.6 million in Q4 2025, $41.7 million for Q3 2025, and $55.5 million during Q2 2025.